Recent interest in Pfizer (PFE) has been driven by U.S. regulators approving IBRANCE as the first CDK4/6 inhibitor ...

Pfizer is undervalued, trading just over 8x 2026 earnings, with improving dividend yield and core business fundamentals.

HSBC downgraded Pfizer Inc. PFE on Monday, citing that the company’s near-term re-rating prospects have weakened despite its ...

Pfizer stock currently trades at less than 9 times forward earnings while yielding more than 6%, making it one of the cheapest large-cap pharmaceutical stocks on the market. That immediately gets ...

Pfizer has spent the past few years trying to convince investors that its post-pandemic business can stand on its own, and Goldman Sachs appears to be asking for more proof before getting more bullish ...

Pfizer is deeply out of favor on Wall Street, which could be a huge opportunity for long-term dividend investors.

Bristol Meyers Squibb and Medtronic are safer healthcare dividend plays these days.

In the latest trading session, Pfizer (PFE) closed at $23.72, marking a -2.47% move from the previous day. The stock trailed ...

PFE trades at just 8x forward earnings while paying a near-7% dividend yield, and the five-year base case model targets $49. Pfizer's Berobenatide GLP-1 posted 16% weight loss at 32 weeks with no ...

Following its June 18, 2026 announcement of a Chief Financial Officer transition, Pfizer reaffirmed the full-year 2026 financial guidance it first issued on December 16, 2025 and reiterated on May 5, ...

Track Pfizer share price today on NSE/BSE with real-time updates. Check stock performance, fundamentals, market cap, shareholding, financial reports, annual & quarterly results, and profit & loss ...

A few years ago, Pfizer (NYSE: PFE) looked unstoppable. The company generated more than $100 billion in annual revenue early in the pandemic, powered by its COVID-19 vaccine and antiviral treatment.